# Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus

> **NCT00064025** · PHASE2 · COMPLETED · sponsor: **Gynecologic Oncology Group** · enrollment: 75 (actual)

## Conditions studied

- Endometrial Adenocarcinoma
- Endometrial Adenosquamous Carcinoma
- Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation
- Recurrent Uterine Corpus Carcinoma
- Stage I Uterine Corpus Cancer
- Stage II Uterine Corpus Cancer
- Stage III Uterine Corpus Cancer
- Stage IV Uterine Corpus Cancer

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Medroxyprogesterone
- **PROCEDURE:** Therapeutic Conventional Surgery

## Key facts

- **NCT ID:** NCT00064025
- **Lead sponsor:** Gynecologic Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2010-09
- **Final completion:** —
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2016-04-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00064025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00064025, "Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00064025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*